Research and original publication material
NOVARTIS AG Received a Patent for Inhibiting the Activity of BCR-ABL1 and Mutants — research background
Research context: This article preserves existing publication material for continuity. Technical, commercial and legal references should be checked against current primary sources before making decisions.
NOVARTIS AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. The disease focus areas of Novartis include Cancer, Cardio-Metabolic, Immunology and Dermatology, Neuroscience, Ophthalmology, and Respiratory. The main platform used by Novartis includes cell and gene therapy.
In India, the Pharmaceutical business of Novartis India Limited is focused on Bone & Pain, Calcium portfolio, Gynecology and Neurosciences and the Generics business is focused on Gynecology, Anti-TB and Anti-infectives.
Novartis AG filed patent application numbered 8547/DELNP/2014 that is titled COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1 ABL2 AND BCR ABL1. This patent application has been granted as Patent Number 317593.
The invention covers Biotechnology compound. The invention relates to compounds of formula I: in which Y, Y1, Y 4, Y5, Y 6, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.
During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act that Claims 1-9 represent the mere discovery of a new form of compounds disclosed in documents D1-D5 which does not result in the enhancement of the known efficacy of that substance.
As a response to the said objection, the applicant submitted that the present invention discloses new chemical entity that is a compound that are not known at the priority date.
Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter.
Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech).
Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.
Discuss a research question related to NOVARTIS AG Received a Patent for Inhibiting
Describe your objective and the evidence you need. The suitability and scope of any research engagement will be confirmed individually.
Discuss a research questionSource and context: Original GIPResearch.com publication dated 2019-09-24. Existing text is retained for historical continuity. Verify time-sensitive matters using official records.

How to patent fintech inventions
Gen AI Innovations
What is Extended Reality
How to patent artificial intelligence based innovations
Patent claim drafting